论文部分内容阅读
目的对比埃索美拉唑镁肠溶片、磷酸铝凝胶、法莫对预防长期服用小剂量阿司匹林患者胃黏膜损伤的临床疗效。方法选择120例需长期口服小剂量阿司匹林老年患者随机分为治疗组和对照Ⅰ组、对照Ⅱ组、对照Ⅲ组各30例,4组患者均给予小剂量阿司匹林片,治疗组加用埃索美拉唑镁肠溶片,对照Ⅰ组仅给予小剂量阿司匹林片,对照Ⅱ组加用胃黏膜保护剂磷酸铝凝胶,对照Ⅲ组加用抑酸剂法莫替丁片。分别在服药3个月后,对4组患者胃镜下黏膜损伤发生率及程度、阿司匹林相关性胃黏膜病变的临床症状加以对比。结果治疗组胃镜下黏膜损伤发生率及程度、阿司匹林相关性胃黏膜病变的临床症状明显低于对照Ⅰ组、对照Ⅱ组、对照Ⅲ组,差异有统计学意义(P<0.05)。结论临床上应严格掌握服用阿司匹林指征,用药前Hp感染者必须行Hp根除治疗,埃索美拉唑镁肠溶片对预防长期服用小剂量阿司匹林致胃黏膜损有显著疗效。
Objective To compare the clinical efficacy of esomeprazole-enteric-coated enteric-coated tablets, aluminum phosphate gel and farprep for the prevention of gastric mucosal injury in long-term aspirin-treated patients. Methods A total of 120 elderly patients with long-term oral low-dose aspirin were randomly divided into treatment group and control group Ⅰ, control group Ⅱ and control group Ⅲ, 30 patients in each group. All 4 patients were given low-dose aspirin tablets. In the control group I, aspirin tablets were given only in small doses, while in the control group II, the gastric mucosal protective agent aluminum phosphate gel was added in the control group II, and the antacid famotidine tablets were added in the control group III. Respectively 3 months after taking the medication, 4 groups of patients with gastroscopic mucosal injury incidence and extent of clinical symptoms of aspirin-related gastric mucosal lesions were compared. Results The incidence and degree of gastroscopic mucosal injury in the treatment group were significantly lower than those in the control group Ⅰ, control group Ⅱ and control group Ⅲ (P <0.05). The clinical symptoms of aspirin-related gastric mucosal lesions in the treatment group were significantly lower than those in the control group. Conclusion Clinical indications of aspirin should be strictly controlled. Before Hp infection, Hp eradication therapy should be performed. Esomeprazole-enteric-coated enteric-coated tablets may have a significant effect on preventing gastric mucosal lesion caused by long-term use of low-dose aspirin.